Aytu BioPharma (LTS:0A8M) Moat Score: 2/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A8M Aytu BioPharma Inc LTS:0A8M
40 GF Score
Price $2.20
GF Value $0.87
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma Moat Score?

Aytu BioPharma LTS:0A8M 40 Moat Score is 2 as of Jul. 18, 2026. GuruFocus rates LTS:0A8M with a GF Score™ of 40/100 and a GF Value™ of $0.87. The stock has 3 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Aytu BioPharma ranks better than 81.57% on this metric.

Aytu BioPharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Aytu BioPharma has No Moat: Aytu BioPharma lacks significant market leadership and has limited intellectual property. The company does not exhibit strong brand strength or customer loyalty, and there are no significant regulatory barriers or cost advantages. Its competitive position is weak, with no clear sustainable advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aytu BioPharma might have No Moat - Very weak/transient advantages.

Aytu BioPharma  (LTS:0A8M) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aytu BioPharma Moat Score Related Terms

LTS:0A8M vs TXMD, CPHI, RMTI: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aytu BioPharma Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Moat Score falls into.


LTS:0A8M
40GF Score
Aytu BioPharma Inc LTS:0A8M
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Aytu BioPharma (LTS:0A8M) has a Moat Score of 2 as of Jul. 18, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Aytu BioPharma ranks #190 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.4%.
Is Aytu BioPharma's Moat Score too high?
Aytu BioPharma's current Moat Score is 2. Based on the distribution chart, Aytu BioPharma ranks #190 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aytu BioPharma has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Moat Score compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #190 out of 1031 companies for Moat Score. This places Aytu BioPharma in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Aytu BioPharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Aytu BioPharma (LTS:0A8M) has a current Moat Score of 2. The stock's GF Value™ is $0.87, compared to a current price of $2.20 — trading 152.9% above its estimated fair value. The current Moat Score is 2. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Aytu BioPharma (LTS:0A8M), the current Moat Score is 2 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (LTS:0A8M) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.20 is trading 152.9% above its estimated GF Value™ of $0.87.

Key valuation signals for LTS:0A8M:

  • Moat Score: 2
  • GF Value™: $0.87 vs. price of $2.20 (152.9% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the LTS:0A8M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Other Exchanges AYTU:USA
Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for LTS:0A8M

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$0.87
GF Value